Journals / Kolon ve Rektum Hastalıkları Dergisi / 2009 / Cilt: 19 - Sayı: 1

The effects of enoxaparine on anastomic healing in rats with chemical ınduced inflammatory bowel disease

Sıçanlarda indüksiyon koliti zemininde enoksaparinin anastomoz iyileşmesi üzerine etkisi

Pages
14–23
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

But these data indicate the need for a larger investigation

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Bowel resection and anastomosis is required in a substantial number of patients with inflammatory bowel disease either in emergent or elective setting during their lifespan.
📊
Key Findings & Data:Patients and Methods: Seventy-two adult male Sprague Dowley(200 g-250 g) rats, divided in 5 groups; Group 1 (n=8): control, Group 2 (n=16): colitis, Group 3:(n=16) colitis + enoxaparine, Group 4: (n=16) colitis + anastomosis, Group 5: (n=16) colitis + enoxiparine + anastomosis.
💡
Conclusion & Impact:But these data indicate the need for a larger investigation
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Bowel resection and anastomosis is required in a substantial number of patients with inflammatory bowel disease either in emergent or elective setting during their lifespan. In this experimental study we aimed to investigate the role of low molecular weight heparin on anastomotic healing in rats with chemical induced inflammatory bowel disease. Patients and Methods: Seventy-two adult male Sprague Dowley(200 g-250 g) rats, divided in 5 groups; Group 1 (n=8): control, Group 2 (n=16): colitis, Group 3:(n=16) colitis + enoxaparine, Group 4: (n=16) colitis + anastomosis, Group 5: (n=16) colitis + enoxiparine + anastomosis. Colitis was induced by intrarectal installation of 2, 4, 6-trinitrobenzene sulphonic acid in 50% ethanol (TBNS). Enoxaparin 80ìg/kg was started intraperitoneally from 3rd day of colitis. At 2nd day of the treatment bowel divided and anastomosed at distal colon with experimental colitis. Each group subdivided in two as to those sacrificed on post operative day1 and 5. During sacrifications colonic resection encompassing anastomoses were performed. Specimens were assessed according to macroscopic and histologic tissue damage scale. Myeloperoxidase (MPO), Lipide Peroxisase (LP), Glutation (GSH) and Hydroxiprolin (HP) levels were also measured from colonic tissues. Results: Enoxaparin therapy decreased the severity of macroscopic damage and the levels of MPO increased the levels of GSH in all groups but no significant difference was observed for microscopic damage and of LP and HP levels. No undesirable effect of enoxiparine on the anastomotic healing was observed. Conclusion: LMWH have no untoward effect on anostomotic healing and it also seems to decrease inflammation and can safely be used during perioperative period. But these data indicate the need for a larger investigation

Özet

Amaç: inflamatuar Barsak Hastalıkları (İBH) sık görülen, kronik bir hastalık grubudur. Bu hastalıkların seyri süresince gelişen komplikasyonları nedeniyle acil ya da planlı cerrahi müdahaleler ve özelikle Crohn Hastalığı'nda zaman zaman hastalıklı barsak segmentinde striktüroplastiler uygulanmaktadır. Ortaya çıkabilecek komplikasyonlar, ‹BH zemininde yapılacak olan anastomozun güvenilirliğine etki eden faktörlerin bilinmesini önemli kılar. Bu çalışmada amacımız düşük molekül ağırlıklı heparininin hem kolit üzerine, hem de kolit zeminindeki anastomoza olan etkisini incelemektir. Hastalar ve Yöntem: Çalışmada 72 adet genç erişkin Sprague- Dawley cinsi sıçan kullanıldı. Sıçanlar 5 gruba ayrıldı. 2, 3, 4 ve 5. gruplar iki alt gruptan oluştu. 1.grup (n=8): kontrol; 2. grup (n=16): kolit; 3. grup (n=16): kolit+enoksaparin; 4.grup (n=16): kolit+anastomoz; 5. grup (n=16): kolit+ enoksaparin +anastomoz şeklinde oluşturuldu. Denekler rektal yoldan trinitro-benzen sülfonik asid verilerek kolit oluşturuldu. Kolitin 3. günü tedavi alan gruplara 80_g/kg enoksaparin intraperitoneal olarak verilmeye başlandı. Tedavinin 2. günü cerrahi uygulanacak grupların kolitli distal kolonlarına tam kat kesi yapılarak anastomoz yapıldı. ‹lk alt gruplar post-op 1.gün, ikinci alt gruplar post-op 5. gün sakrifiye edildiler. Alınan dokular makroskopik hasar skalası ve mikroskopik hasar kriterlerine göre değerlendirilirken, dokularda myeloperoksidaz aktivitesi(MPO), lipid peroksidaz (LPO), glutatyon(GSH) ve hidroksiprolin(HP) düzeyleri ölçüldü. Bulgular: Tedavi alan, cerrahi uygulanmış ve uygulanmamış tüm gruplarda makroskopik hasarın ve MPO düzeylerinin azaldığı, GSH düzeylerinin ise arttığı saptanırken mikroskopik hasar, LPO ve HP düzeylerinde anlamlı bir fark gözlenmemiştir. Enoksaparinin anastomoz üzerine herhangi bir yan etkisi saptanmamıştır. Sonuçlar: Düşük Molekül Ağırlıklı Heparinler, ‹BH zemininde yapılacak anastomozlarda iyileşme üzerine olumsuz etkileri olmadığından ve inflamasyonu azalttıklarından perioperatif dönemde kullanılabilirler, ancak bu verilerin desteklenebilmesi için daha çok kontrollü klinik ve deneysel çalışmaya ihtiyaç vardır.

🔖

Cite This Article

YILDIRIM, S., BAYKAN, A., ÖNER, M., KÖKSAL, M. H., ERTÜRK, A. D., CELAYİR, M. F. (2022). The effects of enoxaparine on anastomic healing in rats with chemical ınduced inflammatory bowel disease. Kolon ve Rektum Hastalıkları Dergisi, Cilt: 19 - Sayı: 1, 14–23. https://ajindex.com/articles/575411

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Malhotra S, Bhasin D, Shafiq N, Pandhi P. Drug treatment of ulcerative colitis: unfractioned heparin, low molecular weight heparins and beyond. Expert Op Pharmacother 2004;5:329-34
  2. Day R., Forbes A. Heparin, cell adhesion and pathogenesis of inflammatory bowel disease. Lancet 1999;354:62-5
  3. Dotan I, Hallak A, Arber N, Santo M, Alexandrowitz A, Knaani Y, Hershkoviz R, Brazowski E, Halpern Z. Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci 2001;46: 2239-44
  4. Dotan I, Hershkoviz R, Karmeli F, et al. Heparin and low-molecular weight heparin (enoxaparin) significantly ameliorate experimental colitis. Aliment Pharmacol Ther 2001;15:1087-97
  5. Levine A, Kenet G, Bruck R, et al. Effect of tissue binding activity of fibroblast growth factor and heparin-binding epidermal growth factor in experimental colitis in rats. Pediat Resear 2002;51: 635-40
  6. Xia B, Han H, Zhang K, et al. Effects of low molecular weight heparin on platelet surface P- selectin expression and serum interleukin-8 production in rats with trinitrobenzen sulphonic acid- induced colitis. World J Gastroent 2004; 10:729-32
  7. He G, Ouyang Q. The preventive and therapeutic effects of low molecular weight heparin on DSS- induced colitis in mice. Sichuan Da Xue Xue Bao Yi Xue Ban 2003;4:701-3
  8. Michell NP, Lalor P, Langman MJ. Heparin therapy for ulcerative colitis? Effects and mechanisms. Europ J Gastroent Hepatol 2001;13:449-56
  9. Wan MX, Liu Q, Wang Y, Thorlacius H. Protective effect of low molecular weight heparin on experimental colitis: role of neutrophil recruitment and TNF-alpha production. Inflamm Res 2002:51:182-7
  10. Papa A, Danese S, Gasbarrini A, Gasbarrini G. Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1403-1409
  11. Salas A, Sans M, Soriano A. Heparin attenuates TNFα induced inflammatory response through a CD11b dependent mechanism. Gut 2000;47:88-96
  12. Carr J. The antiinflammatory action of heparin: heparin as an antagonist to histamine, bradykinin and prostaglandin E1. Tromb Res 1979;16:507-16
  13. Folwaczny C. Coagulation system and inflammatory bowel disease: therapeutic and pathophysilogic implications. Z Gastroenterol. 2002;40: 991-98
  14. Szabo S, Kusstatscyher G, Sakoulas G. Growth Factors: 'endogenous drugs' for ulcer healing. Scand J Gastroent 1995;30:15-18. 15.